|
Synonyms: ADCT-402 | ADCT402 | loncastuximab tesirine-lpyl | RB4v1.2-SG-3249 | Zynlonta®
loncastuximab tesirine is an approved drug (FDA (2021), EMA (2022))
Compound class:
Antibody
Comment: Loncastuximab tesirine (ADCT-402) is an antibody-drug conjugate that delivers the toxic payload teserine (pyrrolobenzodiazepine dimer SG3249, which acts as a DNA alkylating and cross-linking agent [4]) to CD19-expressing B cells [6]. The linker contains a valine-alanine dipeptide bridge that is specifically recognized and cleaved by cathepsin B (CTSB; which is highly expressed by tumour cells) [3,5].
|
| References |
|
1. Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid E, O'Connor OA, Feingold JM, Ardeshna KM, Townsend W, Solh M et al.. (2021)
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood, 137 (19): 2634-2645. [PMID:33211842] |
|
2. Jain N, Stock W, Zeidan A, Atallah E, McCloskey J, Heffner L, Tomlinson B, Bhatnagar B, Feingold J, Ungar D et al.. (2020)
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. Blood Adv, 4 (3): 449-457. [PMID:32012214] |
|
3. Jin C, Ei-Sagheer AH, Li S, Vallis KA, Tan W, Brown T. (2022)
Engineering Enzyme-Cleavable Oligonucleotides by Automated Solid-Phase Incorporation of Cathepsin B Sensitive Dipeptide Linkers. Angew Chem Weinheim Bergstr Ger, 134 (13): e202114016. [PMID:38505643] |
|
4. Tiberghien AC, Levy JN, Masterson LA, Patel NV, Adams LR, Corbett S, Williams DG, Hartley JA, Howard PW. (2016)
Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload. ACS Med Chem Lett, 7 (11): 983-987. [PMID:27882195] |
|
5. Xiao D, Zhao L, Xie F, Fan S, Liu L, Li W, Cao R, Li S, Zhong W, Zhou X. (2021)
A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate. Theranostics, 11 (6): 2550-2563. [PMID:33456559] |
|
6. Zammarchi F, Corbett S, Adams L, Tyrer PC, Kiakos K, Janghra N, Marafioti T, Britten CE, Havenith CEG, Chivers S et al.. (2018)
ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood, 131 (10): 1094-1105. [PMID:29298756] |